About 4.4 million new cancers are detected every year in Europe as well as about 2 million cancer related deaths. Unfortunately, some cancers are first diagnosed in advanced stages which entail more intensive and expensive treatments with a greater risk of side effects. Detecting cancers at an early / local stage is vital for successful treatments, fewer treatment costs and lower toxicities. Trucheck™ is the culmination of years of collaborative international research and innovation on circulating tumour cells and has been developed, tested and validated on > 57.000 individuals.
Trucheck™ technology
- Trucheck™ detects circulating tumour cells (CTCs) which are released by malignant tumours, but not from non-cancerous (normal / benign tumour / inflammatory) tissue.
- Trucheck™ intelli can distinguish up to 70 types of solid tumours which account for ~81% of all cancer cases and ~84% of all cancer related deaths in Europe.
- In clinical studies, Trucheck™ has a sensitivity of 88% in the detection of cancer at all stages and types.
- Real-world data has shown a sensitivity, depending on the tumor, of 65% – 89% and a specificity of 96% – 99%.
Reviews
There are no reviews yet.